摘要
目的:探讨卡培他滨联合常规化疗治疗晚期胃癌疗效、不良反应及对血清基质金属蛋白酶2(matrix metalloproteinase 2,MMP-2)及MMP-9的影响,为临床治疗晚期胃癌提供临床依据.方法:收集南华大学附属第二医院2011-10/2013-10收治的120例胃癌患者,随机将其分为对照组57例与观察组63例.对照组给予常规多西紫杉醇和顺铂治疗,观察组在常规治疗基础上给予卡培他滨治疗,观察并比较两组患者疗效、生存率、不良反应及对血清MMP-2和MMP-9水平的影响.结果:两组患者治疗有效率比较差异无统计学意义(P>0.05),但观察组6 mo与1年生存率分别为88.9%与77.8%,均显著高于对照组患者(73.7%vs 59.6%),差异具有统计学意义(P<0.05).观察组患者在骨髓抑制及胃肠道反应方面显著高于对照组患者,差异具有统计学意义(P<0.05),两组患者其他方面不良反应差异无统计学意义.两组治疗后与治疗前相比,血清MMP-2与MMP-9水平均有所降低,差异均具有统计学意义(P<0.05).与对照组相比,观察组治疗后MMP-2与MMP-9均显著低于对照组治疗后血清水平,差异均具有统计学意义(P<0.05).结论:卡培他滨联合常规化疗治疗晚期胃癌疗效确切,安全性较好,并且可显著降低M M P-2与M M P-9的血清水平,值得临床上进一步深入研究.
AIM:To investigate the curative efficacy of capecitabine in the treatment of patients with advanced gastric cancer(AGC) as well as its effect on serum levels of matrix metalloproteinase(MMP)-2 and MMP-9.METHODS:One hundred and twenty AGC patients were randomly divided into either a control group(n- 57) or an observation group(n- 63).The control group was treated with docetaxel in combination with cisplatin,and the observation group was treated with capecitabine on the basis of docetaxel plus cisplatin.The curative efficacy,survival rates at 6 mo and 1 year,toxic side effects and serum levels of MMP-2 and MMP-9 were compared for the two groups.RESULTS:The curative efficacy between the observation group and the control group had no significant difference(P〈0.05).The 6-mo and 1-year survival rates were significantly higher in the observation group than in the control group(P 005).Except for myelosuppression and gastrointestinal reactions,the two groups had no significant difference in toxic side effects.Compared with those before treatment,serum MMP-2 and MMP-9 levels both decreased significantly,and the decrease was more significant in the observation group(P〈0.05).CONCLUSION:Treatment with capecitabine in combination with docetaxel and cisplatin for AGC therapy is effective and safe,and can significantly decrease serum levels of MMP-2and MMP-9.
出处
《世界华人消化杂志》
CAS
2015年第7期1136-1140,共5页
World Chinese Journal of Digestology
基金
国家自然基金资助项目
No.81071965~~